Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ASTELLAS FARMA LDA

NIF 502540249
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €17,406,140 31 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €17,406,140 31 contracts
A2 · Late Publication €7,543,011,444 1,541 contracts
Contract published to BASE more than 10 days after the signing date
LOW €7,543,011,444 1,541 contracts
A5 · Threshold Splitting €8,645,097 38 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €8,645,097 38 contracts
A6 · Low Competition €2,996,519 28 contracts
Only one bidder participated in a competitive procedure
MEDIUM €2,996,519 28 contracts
A9 · Abnormal Price Reduction €9,136,952,664 653 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €9,136,952,664 653 contracts
C3 · Missing Mandatory Fields €8,086,995 41 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €8,086,995 41 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

166
€428,470,831
249
€417,372,943
55
€414,367,780
80
€404,546,691
22
€381,327,956
104
€381,137,980
26
€374,580,602
62
€373,018,895
19
€359,595,982
236
€350,867,378
63
€349,966,981
23
€335,053,171
18
€331,656,775
26
€327,454,836
12
€320,462,812
124
€272,332,829
154
€271,349,399
19
€269,977,703
28
€268,927,100
12
€267,768,845
Page 1 of 3 · 53 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 38 contracts

040100302026 - ENFORTUMAB VEDOTINA PÓ CONC SOL INJ FR IV
PT · 12781266 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€144,000 2026-01-13
BEAD20250508 - AQUISIÇÃO DE ANTIHORMONAS ANTI - ANDROGENIOS - ENZALUTAMIDA
PT · 12134453 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,664 2025-12-18
ANTIIHORMONAS ANTI-ANDROGENIOS - ENZALUTAMIDA
PT · 12018685 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,664 2025-12-05
251Y000394/13559 - VÁRIOS MEDICAMENTOS
PT · 11968342 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€148,226 2025-11-20
Q1/2318/2025 - AGREGAÇÃO URGENTE - MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 11977153 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,294,078 2025-10-22
ANTIHORMONAS ANTI-ANDROGENIOS - ENZALUTAMIDA
PT · 11725745 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,664 2025-09-17
ANTIHORMONAS ANTI-ANDROGENIOS - ENZALUTAMIDA - 1 MÊS
PT · 11623521 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,664 2025-08-05
Aquisição de Medicamentos do foro oncológico e imunomoduladores, ao abrigo do acordo quadro 2023/491, para o ano 2025
PT · 11749027 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€144,806 2025-04-10
Aquisição de ENFORTUMAB VEDOTINA 20 MG PÓ CONC SOL e ENFORTUMAB VEDOTINA 30 MG PÓ CONC SOL INJ FR IV
PT · 11315583 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€148,200 2025-03-25
MEDICAMENTOS EXCLUSIVOS ASTELLAS FARMA, LDA
PT · 11191695 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€72,000 2025-01-07
Fornecimento de Medicamentos do Aparelho Geniturinário e Medicamentos para Nutrição Parentérica AQ 495/2023 e 493/2023
PT · 11514060 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€71,923 2025-01-06
EXCL ASTELLAS - ENFORTUMAB VEDOTINA
PT · 10691621 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€72,000 2024-04-26
241G000134-CITOSTATICOS E IMUNODEP.
PT · 10562530 · Ajuste Direto Regime G...
A5 · Threshold Splitting A6 · Low Competition
€148,407 2024-02-15
IMUNOMODULADORES - TACROLIMUS - 1º SEMESTRE
PT · 9799340 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,381 2023-02-13
MEDICAMENTOS
PT · f6901ea6d90aac24eec3 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€19,201 2022-06-01
IMUNOMODULADORES - TACROLÍMUS
PT · 7661073 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€146,190 2021-02-05
ENZALUTAMIDA; MICAFUNGINA
PT · 7489712 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€148,899 2021-02-02
ENZALUTAMIDA; MICAFUNGINA
PT · f9b95c83bf53eae4839f · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€148,899 2021-02-02
EAD20200145 - ENZALUTAMIDA
PT · 7564169 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€144,711 2020-11-09
ENZALUTAMIDA 40 MG CÁPS.
PT · 7100312 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€145,379 2020-08-11
Enzalutamida 40 mg Cáps e Cáps moles
PT · 6832576 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€145,379 2020-07-16
Enzalutamida 40 mg cáps.
PT · 6860648 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€145,379 2020-06-25
ENZALUTAMIDA 40MG CÁPS.
PT · 6931902 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€145,379 2020-05-27
41-4011-2019-31 medicamentos do foro oncologico
PT · 6197441 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€71,618 2019-12-20
61009519-AQ.urgente-medicamentos diversos
PT · 5874141 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€71,302 2019-02-01
Aquisição de medicamentos - Enzalutamida e Micafungina
PT · 4578486 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€146,680 2018-06-19
Aquisição de medicamentos foro oncológico
PT · 4277007 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€71,595 2018-01-24
P259-AC-2017-11_AQUISIÇÃO DE MEDICAMENTOS DESENCADEADA PELA SPMS, EPE NO ÂMBITO DO DESPACHO 1571/B DE 2016 AO ABRIGO DO ACORDO QUADRO 2015/6 - MEDICAMENTOS DO FORO ONCOLÓGICO
PT · 3243177 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€146,346 2017-03-17
AD para Aquisição de Medicamentos Ùnicos Astellas (CPA 2015/06)
PT · 2887218 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,902 2017-01-06
Enazalutamida 40mg Cáps
PT · 2474775 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,480 2016-09-28
Enzalutamida 40 mg cáps (CPA 2015/06)
PT · 2300637 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,480 2016-07-19
Enazalutamida 40mg Cáps
PT · 2261631 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,480 2016-06-28
Enazalutamida 40mg Cáps
PT · 2197637 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,480 2016-05-13
Micafungina 100 mg Pó sol inj Fr IV
PT · 2048724 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€4,999 2016-03-02
Medicamentos Anestésicos e Relaxantes Musculares
PT · 2239989 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€73,544 2016-01-20
AD376-2015-RENOVAÇÃO DO CONTRATO DO AD376-2014 PARA 2016
PT · 2504016 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€74,994 2016-01-11
510914/15 - Aquisição de Tacrolímus 5 mg cáps. LP e Tacrolímus 3 mg cáps. LP
PT · 1776797 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,666 2015-11-09
CAPSAICINA 179MG ADESIVO CUTANEO
PT · 1451338 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,437 2015-05-05
Overview
Total Value Won
€9,273,228,876
Contracts Won
2,183
Score 72430 · CRITICAL RISK
NIF
502540249
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.L. [P-c41c]
    Gerente
    since 2023-11-21
  • J.M. [P-507f]
    Gerente
    since 2024-06-28
  • R.I. [P-b4a3]
    Gerente
    since 2026-03-26
  • R.M. [P-6a6b]
    Gerente
    since 2016-09-27
  • R.M. [P-6a6b]
    Gerente
    since 2024-06-28
  • A.P. [P-d113]
    Sócio
    since 2015-04-10
  • A.P. [P-7a72]
    Sócio
    since 2015-04-10
  • A.G. [P-3e39]
    Gerente
    2011-06-17 → 2016-03-24
  • D.B. [P-b4bb]
    Gerente
    2016-04-06 → 2018-09-26
  • E.T. [P-f3f8]
    Gerente
    2016-02-22 → 2018-09-17
  • E.T. [P-f3f8]
    Gerente
    2021-01-15 → 2021-09-20
  • F.J. [P-4794]
    Gerente
    2016-04-06 → 2026-03-26
  • G.K. [P-c72f]
    Gerente
    2011-06-17 → 2016-02-22
  • H.Z. [P-e82d]
    Gerente
    2021-09-22 → 2023-10-30
  • J.H. [P-32ac]
    Gerente
    2016-02-22 → 2016-04-06
  • N.J. [P-1516]
    Gerente
    2011-06-17 → 2016-02-22
  • P.A. [P-dc72]
    Gerente
    until 2011-06-01
  • R.J. [P-8e74]
    Gerente
    2011-06-17 → 2016-09-05
  • Y.I. [P-0359]
    Gerente
    until 2015-04-07
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned